About us
- Since its inception, OBD has focused on:-
- OBD is developing a netwok of regional licencees in South-East Asia, Australia, Europe and the USA, to commercialise its technology in different diagnostic and therapeutic areas.
- In the short term OBD is looking at specific diseases and drug targets where the technology would have the greatest effect including breast cancer, prostate cancer, liver cancer and melanoma.
- OBD holding company is registered in England and Wales and has subsidiaries in Singapore and Australia.
| » | developing and standardising its technology for a set of unique diagnostic applications. |
| » | establishing collaborations and feasibility studies with leading academic research groups. |
| » | filing patents, and securing newly generated intellectual property and technical know-how. |